Clinical trials: Senior
Influenza Vaccination in Seniors
Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists
The application of the TLR7/8 (Toll Like Receptor) agonist gel (immune response helper) resiquimod will enhance the immune response to the intradermal influenza vaccine in seniors 65-75 years of age.
- Trial name
- NCT01737580
- Testing
- resiquimod
- Where
- Canada
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of British Columbia